...the primary endpoint in the Phase II LANTERN trial of LYR-210 to treat chronic rhinosinusitis, Lyra Therapeutics Inc....

...Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD). Ear, nose and throat diseases company Lyra Therapeutics Inc....
...Sawka, BioCentury Staff Akcea Therapeutics Inc. ImCheck Therapeutics S.A.S. IsoPlexis Corp. Abeona Therapeutics Inc. Evaxion Biotech A/S Strongbridge Biopharma plc Sotio a.s. Rexgenero Ltd. Lyra Therapeutics Inc. ImmunoMolecular...

...Wolfe, Associate Editor, Data & Analytics Legend Biotechnology Co. Ltd. Applied Molecular Transport Inc Pliant Therapeutics Inc. Ayala Pharmaceuticals Inc. Lyra Therapeutics Inc. ORIC...

...Pharmaceuticals Inc. (NASDAQ:AYLA) priced a bumped-up offering at its midpoint last week, while ENT company Lyra Therapeutics Inc....

...Inc. (NASDAQ:AYLA) priced a bumped-up offering at its midpoint last week, while chronic rhinosinusitis company Lyra Therapeutics Inc....

...in 2019 (see “Follow-on Market Poised for Comeback” ). Ayala’s public debut follows that of Lyra Therapeutics Inc....

...Ayala would raise $49.5 million and be valued at $181.7 million. The filing comes after Lyra Therapeutics Inc....

...in the final hours of a month in which biotech indexes climbed by double digits. Lyra Therapeutics Inc....
...the Dow Jones Industrial Average gained 11%, while the NASDAQ Composite rose 15%. Paul Bonanos, Associate Editor Lyra Therapeutics Inc. IPO...

...and begin construction of a GMP facility. Lyra sets terms for planned IPO Rhinosinusitis company Lyra Therapeutics Inc....
...a 47.6% stake in Immunomic. Five members of HLB Co. Ltd. will join Immunomic’s board. BioCentury Staff Lyra Therapeutics Inc. HebeCell...

...“Passage Prices Despite Headwinds” ). Elsewhere in the queue are Ayala Pharmaceuticals Inc. and Lyra Therapeutics Inc....